GAMMA Investing LLC Grows Stock Holdings in Genmab A/S (NASDAQ:GMAB)

GAMMA Investing LLC lifted its holdings in Genmab A/S (NASDAQ:GMAB) by 194.0% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 1,135 shares of the company’s stock after purchasing an additional 749 shares during the period. GAMMA Investing LLC’s holdings in Genmab A/S were worth $34,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Pinnacle Bancorp Inc. lifted its position in shares of Genmab A/S by 315.8% in the 4th quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company’s stock worth $27,000 after purchasing an additional 638 shares during the period. Principal Securities Inc. purchased a new stake in shares of Genmab A/S in the 4th quarter worth approximately $77,000. Advisors Preferred LLC purchased a new stake in shares of Genmab A/S in the 4th quarter worth approximately $82,000. Exchange Traded Concepts LLC lifted its position in shares of Genmab A/S by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 3,691 shares of the company’s stock worth $118,000 after purchasing an additional 936 shares during the period. Finally, Barometer Capital Management Inc. purchased a new stake in shares of Genmab A/S in the 4th quarter worth approximately $121,000. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Analysts Set New Price Targets

GMAB has been the subject of several research reports. Morgan Stanley reaffirmed an “underweight” rating on shares of Genmab A/S in a research report on Tuesday, March 26th. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research report on Thursday, June 20th. Finally, Truist Financial increased their target price on shares of Genmab A/S from $50.00 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, June 4th. Three analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Genmab A/S presently has a consensus rating of “Hold” and a consensus price target of $49.25.

Genmab A/S Trading Down 0.2 %

Shares of Genmab A/S stock opened at $25.78 on Wednesday. Genmab A/S has a 12-month low of $25.38 and a 12-month high of $42.72. The firm has a market capitalization of $17.05 billion, a price-to-earnings ratio of 21.48, a PEG ratio of 0.95 and a beta of 0.99. The firm’s 50 day simple moving average is $28.14 and its two-hundred day simple moving average is $29.21.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $0.16 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.16. Genmab A/S had a net margin of 30.74% and a return on equity of 18.90%. The business had revenue of $603.30 million for the quarter, compared to analyst estimates of $594.23 million. On average, sell-side analysts predict that Genmab A/S will post 1.11 EPS for the current fiscal year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.